Home > Oncology > Darolutamide lowers risk of death by 31% for some prostate-cancer patients

Darolutamide lowers risk of death by 31% for some prostate-cancer patients


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22
Journal
New England Journal of Medicine
Reuters Health - 09/09/2020 - The new prostate-cancer drug darolutamide lowers the risk of death by 31% at the three-year mark for men with nonmetastatic, castration-resistant prostate cancer, according to new data from the phase-3 ARAMIS study. Finland's Orino and Germany's Bayer, which paid for the test, had previously announced that the drug, sold under the brand name Nubeqa, had produced a median metastasis-free survival of 40.4 months versus 18.4 months with placebo. The new report, in the New England Journal of Medicine, says that overall survival at three years was 83% with the drug versus 77% with placebo (P=0.003). The drug is given in conjunction with androgen-deprivation therapy. The study involved 1,509 men, all with a PSA doubling time of 10 months or less. The metastasis-free survival data served as the basis for the drug's approval by the U.S. Food and Drug Administration in July 2019. The time to pain progression, a secondary end...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on